AVITA Medical (RCEL) News & Sentiment

After Sales Rebound In January, AVITA Is Set Up For A Monster Year

AVITA Medical invites shareholders and prospective investors to attend its investor webinar briefing and presentation on February 18, 2025 at 2:00PM PT.

AVITA Medical's stock plummeted 36.4% after a significant Q4 sales miss, highlighting a pattern of guidance misses. Management's breakeven target shifted to Q4 2025. It also gave 2025 sales guidance of $100-$106 million. The Company will be forced to repay its $40 million OrbiMed loan if its sales follow my projections and company guidance.

AVITA Medical: A Dip Buy As 2025 Looks Bullish With Cohealyx And RECELL GO Mini

On Tuesday, Avita Medical, Inc. RCEL revised its revenue guidance for the fourth quarter and full year of 2024.

AVITA Medical's Australia-listed shares sank nearly 19% on Wednesday, set for their worst day in 15 months, after the regenerative medicine firm cut its forecast for the fourth time in five quarters and pushed out its profitability target.

AVITA Medical expects fourth quarter 2024 commercial revenue of approximately $18.4 million, reflecting growth of around 30% over the same period in 2023.

AVITA Medical's Q3 report showed strong sequential sales growth and a lower burn rate. My confidence in it reaching breakeven by Q3 2025 has increased. The transition to RECELL GO has been highly successful, with 75% of the US sales base switching from the manual version. This is driving increased utilization. The total addressable market for AVITA's new ecosystem of products has expanded significantly, with the burning market TAM increasing from $450 million to $1.5 billion.

VALENCIA, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has approved its premarket approval (PMA) supplement for RECELL GO® mini.